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While scaffold proteins are thought to be key components of signaling pathways, their exact function is
unknown. By preassembling multiple components of signaling cascades, scaffolds are predicted to influence the
efficiency and/or specificity of signaling events. Here we analyze a potential scaffold of the Ras/mitogen-
activated protein kinase (MAPK) pathway, kinase suppressor of Ras (KSR), by generating KSR-deficient mice.
KSR-deficient mice were grossly normal even though ERK kinase activation was attenuated to a degree
sufficient to block T-cell activation and inhibit tumor development. Consistent with its role as a scaffold,
high-molecular-weight complexes containing KSR, MEK, and ERK were lost in the absence of KSR. This
demonstrates that KSR is a bona fide scaffold that is not required for but enhances signaling via the
Ras/MAPK signaling pathway.
Sequential protein kinase cascades are highly conserved sig-
naling pathways used by cells to respond to extracellular stim-
uli (18, 45, 65). While the kinase components of these path-
ways have been well described, how multiple kinases are
regulated spatially or temporally is less well understood. A
study of scaffold proteins, which by definition preassemble
multiple components of a protein kinase cascade, can poten-
tially explain how these signaling pathways are organized (5,
17, 32, 47, 48, 63, 64).
Scaffolds may serve different functions in signaling pathways.
In some systems, scaffolds are integral components required
for signaling events to occur. In budding yeast cells, inactivat-
ing the mitogen-activated protein kinase (MAPK) scaffold pro-
tein, STE5, blocks mating. Genetic studies demonstrate that
STE5 is crucial for specifically directing the yeast MAPK com-
ponents to activate the pheromone response pathway (re-
viewed by Elion [17]). In another example, the Drosophila
photoreceptor scaffold protein InaD is not required but can
dramatically influence the efficiency of signal transduction
(59).
While scaffolds for the MAPK pathway are well documented
in yeast, fly, and worm cells, deducing the physiologic impor-
tance and function of mammalian homologs has been less
successful. Several proteins have been identified as potential
mammalian scaffolds based on the ability of a particular pro-
tein to bind multiple kinases of a signaling pathway (10, 46, 70).
To date, only one scaffold protein, JIP-1, has been examined in
a physiologic context. JIP-1-deficient animals demonstrated
defective JNK activation in response to excitotoxic and anoxic
stress in the brain (64). There has not been, however, an
in-depth analysis of candidate proteins in a physiologic context
for the Ras/MAPK pathway. Here we analyze a putative
MAPK scaffold, kinase suppressor of Ras (KSR). KSR was
cloned in Caenorhabditis elegans and Drosophila melanogaster
(31, 53, 55). Because the loss of KSR suppresses the phenotype
conferred by an activated Ras molecule, KSR is thought to play
a positive role in Ras/MAPK signaling. Genetic epistasis ex-
periments position KSR after Ras and before MEK in the
signaling pathway.
KSR remains an intriguing protein because its biological
importance and precise role in the mammalian Ras/MAPK
pathway are unclear. While the loss of KSR expression causes
embryonic lethality in D. melanogaster, loss of KSR has little
effect in C. elegans (31, 53, 55). While genetics support the idea
that KSR is a positive regulator of the Ras/MAPK pathway,
overexpression studies in mammalian cells suggests that KSR
can both activate and inhibit Ras/MAPK signaling (6, 11, 26,
36, 52, 56, 71). One hypothesis that can reconcile these con-
flicting data proposes that KSR functions as a scaffold protein
in the Ras/MAPK pathway since KSR can bind to both MEK
and ERK (37, 38, 71). To support this, recent data demonstrate
that KSR, when overexpressed in COS cells, can recruit MEK
to the plasma membrane in response to epidermal growth
factor (EGF) (39).
To test the role of KSR as a MAPK scaffold in vivo, KSR-
deficient mice were generated. While KSR was not required
for development, the loss of KSR decreased MAPK activation.
* Corresponding author. Mailing address: Department of Pathology
and Immunology, Washington University School of Medicine, 660 S.
Euclid Ave., Box 8118, St. Louis, MO 63110. Phone: (314) 362-6311.
Fax: (314) 362-8888. E-mail: shaw@immunology.wustl.edu.
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The ability to study tissues and cells lacking KSR provided us
with a unique opportunity to examine high-molecular-weight
signaling complexes in the presence or absence of KSR, as well
as its effect on MAPK signaling. We show here that KSR forms
a ternary complex with both MEK and ERK and that the
absence of KSR significantly diminishes MAPK signaling.
These data support the idea that KSR is a MAPK pathway
scaffold that is not required but functions mainly to facilitate
MAPK activation.
MATERIALS AND METHODS
Construction of the KSR targeting vector and screening of mice. Standard
gene-targeting techniques and homologous recombination were used to generate
KSR/ mutant mice (57). The CA2 domain of the KSR protein was targeted
and mice were screened by Southern blotting. Southern blotting confirmed the
integrity of both the 5 and 3 targeting arms. Reverse transcription-PCR (RT-
PCR) analysis showed that while the RNA machinery can splice out the neomy-
cin cassette, it results in an out-of-frame transcript after amino acid 294. Het-
erozygous mice were bred and KSR/ mice were screened with PCR primers
specific for nucleotides 883 to 1008 in the KSR coding sequence. DO11.10
T-cell-receptor-positive (TCR) mice were screened with primers specific for the
alpha- and beta-chains of the DO11.10 TCR. In addition, a clonotypic mono-
clonal antibody, kJ1-26, was used to stain peripheral lymphocytes to detect T
cells expressing the DO11.10 TCR. Mice transgenically expressing the polyoma-
virus middle T antigen (MT) were screened with primers generated to detect the
splice A and splice B isoforms of the MT coding sequence.
Generation of MEFs. Mouse embryonic fibroblasts (MEFs) were derived from
13.5-day-old embryos. After removal of the head and internal organs, embryos
were rinsed with phosphate-buffered saline (PBS), minced, and digested with
trypsin-EDTA (0.5% trypsin, 0.53 mM EDTA per embryo) at 37°C. Trypsin was
inactivated by addition of Dulbecco minimal Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential amino
acids, 100 U of penicillin per ml, and 100 g of streptomycin per ml. Cells were
placed plates in T175 flasks and then incubated at 37°C in a 10% CO2 humidified
chamber.
KSR protein analysis. Lysates from spleen, thymus, and brain tissues were
prepared from wild-type and KSR/ mice. Tissues were homogenized in mam-
malian cell lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 2 mM EDTA, 2 mM
dithiothreitol [DTT], 0.5% NP-40, 100 M sodium orthovanadate, 2 mM phe-
nylmethylsulfonyl fluoride, 20 M leupeptin, 20 M pepstatin) by using pre-
chilled glass homogenizers (2-ml capacity) and then passed three times through
a 26-gauge needle. Lysates were cleared of insoluble debris by centrifugation at
4°C and 14,000 rpm for 10 min. The protein concentration was assessed by using
a BCA Protein Assay Kit (Pierce). Studies were done either on immunoprecipi-
tated KSR complexes or on cellular bulk lysates. The protein concentration was
diluted to 1 mg/ml, and 1 ml was used for immunoprecipitation by using a goat
anti-KSR (c-19) polyclonal antibody (Santa Cruz Biotechnology) and incubated
overnight at 4°C. Protein A-Sepharose (Sigma) was then added for 1 h. For
Western blot analysis, the immunoprecipitates were resolved by sodium dodecyl
sulfate-polyacrylmide gel electrophoresis (SDS-PAGE) on 8% polyacrylamide.
Immunoblotting was performed by using a rabbit polyclonal anti-KSR antibody
generated to amino acids 118 to 248 of KSR (38) or a goat polyclonal anti-KSR
antibody generated against amino acids 855 to 871 of KSR (c-19; Santa Cruz
Biotechnology). Secondary donkey anti-rabbit horseradish peroxidase (HRP)-
conjugated antibodies (Jackson Immunoresearch) were used at a 1:10,000 dilu-
tion. A Supersignal enhanced chemiluminescence detection kit (Pierce) was used
to evaluate chemiluminescence on Kodak X-Omat AR film.
FACS analysis. Fluorescence-activated cell sorting (FACS) analysis was per-
formed on spleen, thymus, and bone marrow tissues homogenized by using
complete DMEM placed on prefrosted glass slides and then cleared of debris by
using cell strainers (Fisher). The cell suspensions were pelleted, washed twice
with FACS staining buffer (PBS, 4% fetal bovine serum, 0.0002% sodium azide),
and counted by using a hemacytometer. They were mixed with various antibodies
conjugated to either fluorescein isothiocyanate (FITC) or phycoerythrin (PE).
Antibodies from PharMingen included PE-conjugated anti-CD4, FITC-conju-
gated anti-CD8, PE-conjugated anti-B220, and biotin-conjugated anti-immuno-
globulin M (IgM). Analyses were performed on a Becton Dickinson FACSCali-
bur instrument equipped with CellQuest software.
Proliferation assays. Proliferation assays were performed with crude spleno-
cytes. A total of 2  105 cells were plated in each well of a 96-well Costar tissue
culture dish and incubated for 24, 48, or 72 h. T-cell mitogens used were
145-2C11 (monoclonal anti-CD3), ovalbumin OVA323-339 peptide, and phorbol
myristate acetate (PMA) plus ionomycin or concavalin A (Sigma). All experi-
ments were done in triplicate. The cells were incubated with 2 Ci of [3H]thy-
midine per well during the final 12 h of culture. The cells were harvested by using
a Skatron Instruments Micro-96 Harvester and counted with a Beckman 6500
multipurpose scintillation counter.
IL-2 bioassays. Interleukin-2 (IL-2) release was measured by using superna-
tants from proliferating T cells and adding them to the cytotoxic-T-cell line
CTLL-2, which is IL-2 dependent for growth. After incubation with supernatants
for 24 h, CTLL-2 cells were pulsed with 2 Ci of [3H]thymidine per well for 8 h.
Cells were harvested in the same manner as for proliferation assays.
Recombinant baculovirus production. For production of recombinant MEK
baculovirus, MEK cDNA was subcloned into the vector pFastBac-HT (Life
Technologies). Recombinant baculoviruses were then generated by using the
Bac-to-Bac HT Baculovirus Expression System (Life Technologies) according to
the manufacturer’s instructions.
Immunoblotting. MEFs, brain tissue, or T cells were isolated and used for
immunoblots or in vitro kinase assays. For RasGTP analysis, 4 107 T cells were
used per time point. After treatment with 100 nM PMA, cell lysates were
incubated with glutathione S-transferase (GST)–RafRBD protein, and protein
complexes were resolved by SDS-PAGE on 15% gels. For analysis of Raf kinase
activity, 4  107 T cells were used per time point. After treatment with 100 nM
PMA, Raf-1 was immunoprecipitated with polyclonal Raf-1 antibody as de-
scribed previously (58) and then incubated in kinase buffer (20 mM Tris [pH 8.0],
150 mM NaCl, 50 mM MgCl2, 2 mM EGTA, 150 M ATP) with recombinant
His-tagged MEK protein produced in Sf9 cells. Kinase assays were performed for
35 min at 37°C, and then proteins were analyzed by SDS-PAGE on 12% gels. For
analysis of ERK activation, 2  105 to 10  105 cells were used per time point.
Poststimulation, cell lysates were prepared, and proteins were resolved by SDS-
PAGE on 12% gels. For detection of RasGTP, a Ras Activation Kit was used
(catalog 17-218; Upstate Biotechnology). For immunoblotting of phosphorylated
MEK, a polyclonal anti-phospho-MEK1/2 antibody (New England BioLabs) was
used at a 1/1,000 dilution. For detection of phosphorylated ERK, a polyclonal
anti-phospho-ERK1/2 antibody (New England BioLabs) was used at a 1:1,000
dilution. For immunoblotting of ERK1 and ERK2, ERK-1 (c-16) and ERK-2
(c-14) (Santa Cruz) were used at 1:500 dilutions. The secondary antibody was
either goat anti-rabbit-HRP antibody (Santa Cruz) used at a 1:3,000 dilution or
donkey anti-rabbit-HRP antibody (Jackson Immunoresearch) at a dilution of
1:10,000. For in vitro kinase assays, MEFs were deprived of serum, stimulated
with either 10 nM EGF or 100 nM PMA for 5 min, and then lysed. Clarified cell
lysates were immunoprecipitated with ERK-1 and ERK-2 antibodies, and in vitro
kinase assays were performed with myelin basic protein as the substrate as
described previously (3); reactions were quenched by the addition of sample
buffer, denatured, and subjected to SDS–12% PAGE. Radiolabeled myelin basic
protein was quantified by using phosphor storage technology (Molecular Dy-
namics).
Gel filtration chromatography. Brain tissue was isolated from wild-type and
KSR/ animals. Whole brains were homogenized in 2-ml glass homogenizers in
buffer B (i.e., 25 mM HEPES [pH 7.4], 25 mM -glycerophosphate, and 2 mM
EDTA supplemented with phenylmethylsulfonyl fluoride, leupeptin, pepstatin,
and benzamidine). Homogenized tissue was then passed through a 26-gauge
needle five times. Samples were spun down in sequential 15,000  g centrifuga-
tion steps at 4°C. Clarified supernatants were then checked for protein concen-
tration by using the BCA Protein Assay Kit (Pierce) and 1.5 mg of total protein
was loaded onto a Superose 6 HR10/30 (Amersham Pharmacia Biotech) gel
filtration column preequilibrated with buffer B at a flow rate of 0.25 ml/min as
described previously (51, 62). Then, 35 1-ml fractions or 70 500-l fractions were
collected, subjected to SDS-PAGE, transferred to nitrocellulose, and immuno-
blotted for MEK-1 (c-18; Santa Cruz), ERK1/2 (c-16; Santa Cruz), KSR (38),
c-Raf-1 (clone 53 [Transduction Labs/PharMingen] or antibodies developed in
our lab [58]), and B-Raf (c-19; Santa Cruz).
Th1/Th2 induction studies. Splenic tissue from DO11.10 TCR wild-type or
KSR/ animals was isolated, homogenized, and subjected to red blood cell lysis.
Ex vivo cultures were then set up with splenic lymphocytes and antigen-present-
ing cells, 1 M ovalbumin peptide, and either (i) gamma interferon (IFN-),
IL-12, and anti-IL-4 or (ii) IL-4, anti-IL-12, and anti-IFN- to induce Th1 or Th2
effector T-cell cultures. At day 3, cultures were split 1:3 and rested until day 7,
when the cultures were restimulated with irradiated antigen-presenting cells and
OVA323-339 peptide. Culture supernatants were then analyzed by enzyme-linked
immunosorbent assay for IFN- and IL-4 production as described previously (24,
35).
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Analysis of mammary tumors in KSR/MT mice. KSR/ mice were bred
three generations onto the C57BL/6 background before being crossed to MT
transgenic mice bred into the C57BL/6 background. F2 littermates were geno-
typed for KSR and MT. MT females were monitored daily starting at 3 weeks
of age for the development of mammary tumors by palpating all five pairs of
mammary glands as described previously (7, 22). Mice were sacrificed after
tumors reached a size of 150 mm2 or larger.
RESULTS
Generation of KSR/ animals. Standard gene-targeting
methods were used to generate KSR/ mice (57). Homolo-
gous recombination was used to replace the exon encoding the
CA2 domain in the N terminus of the murine KSR gene locus
with the neomycin resistance gene (Fig. 1A). Western blotting
with both an N-terminal and a C-terminal specific antibody
confirmed that full-length KSR, as well as any truncated form
of KSR, was undetectable in the knockout animals (Fig. 1B
and C). RT-PCR analysis showed that, while the RNA ma-
chinery can splice out the neomycin cassette, it results in an
out-of-frame transcript (see Materials and Methods). Knock-
out animals were viable and phenotypically normal. The his-
tology of all tissues was normal (data not shown). These results
indicate that KSR is not required for development.
Defective ERK activation in KSR/ fibroblasts. To test the
function of KSR in the MAPK pathway, MEFs were generated
from wild-type and KSR/ animals. ERK activation was
tested with two well-known ERK activators: EGF and PMA (4,
27). Both stimuli strongly induced ERK activity in wild-type
cells, as detected by measuring ERK phosphorylation (Fig. 2A)
or by in vitro kinase assays (Fig. 2B and C). In contrast,
KSR/ MEFs displayed a consistent 50% reduction in ERK
activation (Fig. 2A) with decreased levels of phosphorylated
ERK and decreased ERK activity detected. Wild-type and
FIG. 1. Generation of KSR/ mice. (A) The targeting strategy is illustrated schematically. Exon 2 encoding the CA2 domain of KSR was
targeted for homologous recombination. (B and C) Western blot analysis of KSR protein expression. Lysates prepared from spleen and thymus
tissues (B) or brain tissue (C) were immunoprecipitated with goat anti-KSR antibodies and resolved by SDS-PAGE. These data were generated
by immunoblotting with a polyclonal rabbit anti-KSR antibody.
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KSR/ cells contain equivalent levels of MAPK. Thus, KSR
potentiates ERK activation.
Normal lymphocyte development in KSR/ animals. Given
the normal phenotype of the KSR/ animals, we focused on
T-lymphocyte development and activation. The development
of T lymphocytes is very well characterized and is known to be
sensitive to changes in the signal transduction pathways. Fur-
thermore, the Ras/MAPK pathway is thought to play an im-
portant role in the positive selection of T cells in the thymus (1,
2, 8, 43, 54).
Thymocytes were isolated from 4- to 5-week-old wild-type or
KSR/ mice and analyzed. The cellularity and CD4/CD8
profiles of thymic T-cell populations in wild-type and KSR/
mice were very similar (Fig. 3A). FACS analysis demonstrated
there were no significant differences in percentages of thymo-
cyte subsets as defined by expression of CD4 and CD8. Periph-
eral T-cell homeostasis was addressed by examining T cells in
the spleen (Fig. 3B). The spleen had a normal cellularity with
a normal distribution of mature T cells.
We analyzed T-cell development in greater detail by breed-
ing KSR/ mice to two different TCR transgenic mice,
DO11.10 and H-Y. T cells expressing the DO11.10 TCR are
activated by a peptide derived from ovalbumin (OVA323-339)
(40), while the T cells expressing the H-Y TCR are activated by
a male-specific peptide (29). The DO11.10 TCR is useful for
studying CD4 T-cell development, while the H-Y TCR is
useful for studying CD8 T-cell development. In both systems,
thymic cellularity and T-cell development were not detectably
impaired (Fig. 3D and data not shown). In repeated experi-
ments, both wild-type and KSR/ thymocytes expressed sim-
ilar levels of TCR (Fig. 3E). Importantly, the presence of
normal numbers of CD4, DO11.10 T cells and the presence
of normal numbers of CD8, H-Y TCR T cells demonstrated
that positive selection was not affected by the loss of KSR (Fig.
3F and data not shown). Therefore, the loss of KSR did not
detectably disrupt or inhibit the normal development of T cells.
We also examined B-cell development. Bone marrow-de-
rived cells were stained for expression of CD43, B220, and IgM
to analyze pro-B, pre-B, and immature B-cell populations (Fig.
3C and data not shown) (23). Normal populations of these
developmental subsets were detected in KSR/ mice. Thus,
the loss of KSR did not detectably affect B-cell development.
Activation of MEK and ERK are impaired during T-cell
activation. T-cell activation was analyzed first by CD3 cross-
linking (Fig. 4A). T-cell proliferation was measured by
[3H]thymidine incorporation. While wild-type and KSR/ T
cells proliferated equally well in response to PMA and iono-
mycin (data not shown), KSR/ T cells exhibited a significant
proliferation defect compared to wild-type T cells when stim-
ulated by CD3 cross-linking. Given this proliferation defect, as
well as the ERK activation defect observed in MEFs, the Ras/
MAPK pathway was examined in greater detail. Since Ras can
be activated by Ras-GRP in a diacylglycerol-dependent fashion
(15, 16), PMA was used as the stimulus to examine Ras, Raf,
MEK, and ERK activation kinetics in T cells.
In response to PMA, wild-type and KSR/ T cells demon-
strated normal RasGTP formation with similar kinetics in wild-
type and KSR/ T cells (data not shown). Further, Raf-1 also
displayed normal activation kinetics in the presence or absence
of KSR. Raf-1 activation was examined by using an in vitro
kinase assay. After PMA treatment, immunoprecipitated
Raf-1 was used to phosphorylate recombinant MEK protein.
Raf-1 activation was measured by immunoblotting for the level
of phosphorylated recombinant MEK protein (Fig. 4B). Loss
of KSR expression did not adversely affect Raf kinase activity
in response to PMA (Fig. 4B, compare lanes 3 and 4 with lanes
7 and 8).
Unlike Ras and Raf, which display normal activation kinet-
ics irrespective of the presence or absence of KSR, the loss of
KSR expression results in impaired MEK activation (Fig. 4C,
compare lanes 3 and 4 with lanes 7 and 8). ERK activation was
also defective. In wild-type T cells (Fig. 4D, lanes 1 to 5) ERK
activation in response to anti-CD3 cross-linking peaked at 2
min and was undetectable by 10 min. In comparison, ERK
activation in KSR/ T cells (Fig. 4D, lanes 6 to 10) was weak
but exhibited similar kinetics. In response to PMA, ERK acti-
FIG. 2. Impaired ERK activation in KSR/ MEFs. (A) Defective ERK phosphorylation after EGF and PMA treatment. MEFs derived from
wild-type (lanes 4 to 6) or KSR/ (lanes 1 to 3) mice were treated with EGF (lanes 2 and 5) or PMA (lanes 3 and 6) or were left untreated (lanes
1 and 4). ERK1/ERK2 immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with antibodies to
phospho-ERK (upper panel) or ERK (lower panel). (B and C) Diminished in vitro ERK kinase activity after EGF (B) or PMA (C) treatment.
Wild-type or KSR/ MEFs were treated with either 10 nM EGF or 100 nM PMA. ERK immunoprecipitates were used to phosphorylate myelin
basic protein in vitro . The results are the means from four independent experiments.
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vation in wild-type T cells (Fig. 4E, lanes 1 to 6) peaked at 2
min and persisted over 10 min. In contrast, the pool of total
phosphorylated ERK in KSR/ T cells was significantly re-
duced, but the kinetics of activation were unchanged (Fig. 4E,
lanes 7 to 12). These results are consistent with genetic epista-
sis experiments which place KSR between Ras and MEK in the
Ras/MAPK pathway.
T-cell activation was next analyzed by using cognate antigen
as the stimulus. DO11.10 transgenic T cells were isolated and
stimulated by using a range of ovalbumin peptide concentra-
tions. T-cell proliferation was measured at 24, 48, and 72 h
after stimulation. KSR/ transgenic T cells proliferated rel-
atively poorly at all time points and at all ovalbumin peptide
concentrations (Fig. 5A). Since secretion of the cytokine IL-2
is largely responsible for T-cell proliferation, we measured
IL-2 secretion by using the IL-2-dependent cytotoxic-T-cell
line CTLL-2 (20). IL-2 secretion from KSR/ T cells was
significantly decreased at all time points compared to that from
wild-type T cells. This demonstrates that KSR/ T cells are
impaired in their ability to secrete IL-2 in response to antigen.
When activated, naive T cells differentiate into cells of the
Th1 or Th2 phenotype. Th1 cells secrete IFN- directing cel-
lular responses during inflammatory immune challenges, while
Th2 cells secrete IL-4, which upregulates antibody-dependent
processes (21, 41). Since perturbation of MAPK signaling pro-
cesses can affect Th1 and Th2 differentiation (14, 34), we were
interested to test whether KSR played a role in Th1 and Th2
differentiation.
DO11.10 T cells were placed under conditions promoting
either Th1 or Th2 differentiation. Compared to wild-type con-
trols, KSR/ T cells did not produce appreciable amounts of
IFN- or IL-4 under either of the induction conditions (Fig.
5C, upper panel). Since the lack of IL-2 secretion might ex-
plain this result, the Th1/Th2 experiment was repeated with
the addition of exogenous IL-2 (Fig. 5C, lower panel). Supple-
mental IL-2 ameliorated the proliferative defect of the
KSR/ T cells, allowing normal Th1 and Th2 differentiation.
In the presence of IL-2, KSR/ Th1 and Th2 cells produced
wild-type levels of cytokines. These data confirm that KSR is
important for efficient T-cell proliferation and also demon-
strate that KSR does not play an instructive role in Th1 or Th2
differentiation.
Loss of high molecular signaling complexes in KSR/
FIG. 3. T-cell and B-cell development is normal in KSR/ mice. (A) FACS analysis of thymocytes. Thymocytes from wild-type or KSR/
mice were isolated and stained for CD4 and CD8 expression. (B) Peripheral T cells isolated from spleen tissues of wild-type or KSR/ mice were
stained for CD4 and CD8 expression. (C) Bone marrow cells isolated from wild-type or KSR/ mice were stained for IgM and B220 expression.
DO11.10 TCR thymocytes from wild-type or KSR/ animals were stained for CD4 and CD8 expression (D), CD3 expression (E), and CD4
expression and kJ1-26 (DO11.10 TCR specific antibody) expression (F).
VOL. 22, 2002 KSR SCAFFOLD FACILITATES MAPK ACTIVATION IN VIVO 3039
 o
n
 January 6, 2014 by W
ashington University in St. Louis
http://m
cb.asm
.org/
D
ow
nloaded from
 
mice. Recent studies demonstrate that KSR can coprecipitate
with components of the Ras/MAPK pathways both in cell lines
and in brain lysates (6, 11, 36, 38, 51, 56, 71) (Fig. 6A). Gel
filtration studies demonstrate that when Raf is overexpressed,
it can be detected in high-molecular-mass complexes of 400 to
500 kDa (62). We hypothesized that KSR, as a potential scaf-
fold, might be required for nucleating a high-molecular-weight
complex containing Raf, MEK, and ERK in vivo.
Cytoplasmic extracts were prepared from wild-type mouse
brain and separated by gel filtration (Fig. 6B). We chose
brain because it is known to express high levels of KSR (38).
Fractions were immunoblotted for KSR, as well as compo-
nents of the MAPK pathway. KSR, RAF, MEK, and ERK
were all found to migrate in fractions containing high-mo-
lecular-mass complexes of 250 to 500 kDa (Fig. 6B). To our
knowledge, this is the first demonstration that endogenous
Raf, MEK, and ERK are contained in high-molecular-mass
complexes in vivo.
We next used gel filtration to analyze brain cytoplasmic
extracts from KSR/ mice. Our finding, supporting a scaf-
folding role for KSR, was that the loss of KSR results in the
shifting of complexes containing MEK and ERK to fractions of
ca. 50 to 250 kDa. Immunoblotting for B-Raf (Fig. 6B) and
c-Raf-1 (data not shown) showed no detectable shift, sug-
gesting that Raf is not a component of the KSR-mediated
scaffold.
While the data are consistent with the idea that KSR is
stably associated with MEK and ERK in vivo, it remained
unclear whether these three proteins form a ternary complex in
vivo. To test this, we attempted to move complexes to the void
volume of the gel filtration column by using antibody cross-
linking. We reasoned that if KSR, MEK, and ERK existed in
the same complex, aggregation with antibodies to MEK should
also move KSR and ERK to the void volume.
Brain cytoplasmic extracts were treated with anti-MEK or a
control antibody, followed by a secondary cross-linking anti-
body to generate large aggregates (Fig. 6C). In the presence of
the anti-MEK, KSR and ERK shifted with MEK to the void
volume of the gel filtration column. This was specific because
the position of B-Raf was unchanged by treatment with the
MEK antibody. In addition, the migration of MEK, ERK, and
KSR complexes was unchanged when lysates were treated with
control antibody. These data establish clearly that ternary com-
plexes containing KSR, MEK, and ERK are stably present in
vivo. Further, these data can potentially explain the activation
defect in the Ras/MAPK signaling pathway in KSR/ cells
since MEK and ERK are inefficiently recruited to upstream
activators such as Ras and Raf-1.
FIG. 4. Loss of KSR expression impairs MEK and ERK, but not Ras or Raf activation. (A) Raf activation and kinase activity are unaffected
in KSR/ T cells. (Top) Following treatment with PMA, immunoprecipitated Raf-1 was used for in vitro kinase assays with recombinant MEK
protein produced from Sf9 cells. Phosphorylated MEK was detected by immunoblotting with an anti-phospho-MEK antibody. (Bottom) Total
recombinant MEK protein was detected by using anti-MEK antibodies. (B) Defective MEK activation in response to PMA. (Top) PMA was used
to stimulate T cells over a time course and lysates were used for immunoblotting. Active MEK was detected by using anti-phospho-MEK
antibodies. (Bottom) Total endogenous MEK was detected by using an anti-MEK antibody. (C) Defective ERK activation in response to CD3
cross-linking. 2C11 was used to activate T cells from wild-type (lanes 1 to 4) or KSR/ (lanes 6 to 9) mice. PMA and ionomycin were used as
a positive control for MAPK activation (lanes 5 and 10). Cell lysates were immunoblotted with anti-phospho-ERK. (D) PMA was used to activate
splenic T cells from wild-type (lanes 1 to 6) or KSR/ (lanes 7 to 12) mice. Cell lysates were immunoblotted with anti-phospho-ERK (top) or
with anti-ERK (bottom).
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Attenuation of tumor growth in KSR/ animals. Since
KSR was originally identified in a system in which Ras was
constitutively active, we were interested in testing whether the
loss of KSR affects the progression of Ras-dependent tumors.
In female mice, the transgenic expression of the polyomavirus
MT causes breast tumors to appear ca. 30 to 40 days after birth
(22). MT is thought to be oncogenic in a Ras-dependent man-
ner through the recruitment of the adaptor protein, Shc, and
the lipid kinase, phosphatidylinositol 3-kinase (13, 60).
KSR/ mice were bred to MT transgenic mice, and the F2
littermate females were monitored. All mice used were bred at
least four generations onto a C57BL/6 background.
MT KSR/ and MT KSR/ female littermate mice
were caged separately after genotyping and checked daily for
tumor formation by palpating each pair of mammary glands on
each mouse. The onset of tumor formation in KSR/ mice
was found to be 35  8 days (n 	 9) (Fig. 7). In comparison,
the onset of tumor formation in KSR/ mice demonstrated
slower kinetics since tumors were not detected until 65  9
days (n 	 8). Immunoblotting demonstrated that breast tu-
mors from wild-type mice express KSR. These findings suggest
that the loss of KSR expression can slow tumor progression in
a well-characterized Ras-dependent tumor model. Further,
this is also in agreement with original genetic screens in which
the loss-of-function KSR mutants were able to suppress the
effects caused by constitutively active Ras transgenes.
DISCUSSION
Here we have established that KSR functions as a scaffold in
the Ras/MAPK signaling pathway in vivo. While this role had
previously been suggested by overexpression data (39, 51) or
coimmunoprecipitation studies (38), our data show for the first
time that KSR at endogenous expression levels exists in a
high-molecular-weight complex that contains both MEK and
ERK. Interestingly, we show that Raf also exists as in a high-
molecular-weight complex, but these complexes are distinct
from the ones containing KSR, MEK, and ERK. The advan-
FIG. 5. KSR/ T cells display an activation defect ex vivo in response to physiologic antigen. (A) Defective T-cell proliferation in response
to anti-CD3. 2C11 was used to stimulate splenic T cells from wild-type or KSR/ mice. T-cell proliferation was measured by quantitation of
[3H]thymidine incorporation. (B) KSR/ or KSR/ T cells transgenically expressing the DO11.10 TCR were used for proliferation assays in
response to ovalbumin peptide (amino acids 323 to 339). After 24 h, cells were pulsed with [3H]thymidine for 12 h, and [3H]thymidine incorporation
was measured. (C) IL-2 release was measured by using the IL-2-dependent cell line CTLL-2. After 24 h, supernatants from proliferating KSR/
or KSR/ T cells were used to stimulate CTLL-2 proliferation. (D) Th1/Th2 effector differentiation was studied by using wild-type and KSR/
T cells under conditions which promote Th1 or Th2 development (top). Exogenous IL-2 was added to compensate for the proliferation defect of
KSR/ T cells (bottom).
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tage of this knockout approach is our ability to study the
function of KSR by analyzing MAPK activation in cells ex-
pressing or lacking KSR. These studies showed that KSR pos-
itively regulates MAPK signaling but is not required for
MAPK signaling. While the sequence of KSR is predicted to
encode for a kinase and work from only one group has re-
ported KSR kinase activity (67, 68, 72), KSR lacks several
conserved residues found in virtually all kinases characterized
to date (22a). A growing body of experimental data support the
idea that KSR has no intrinsic kinase activity (36, 38, 39, 61).
KSR as a scaffold. The prototypical MAPK scaffold is STE5
from Saccharomyces cerevisiae. Yeast cells use the same three
MAPKKK/MAPKK/MAPK proteins—STE11, STE7, and
FUS3—to respond to several different stimuli (as reviewed by
Elion [17]). The function of these scaffolds is thought to be
critical for the routing of specific extracellular signals to the
MAPK pathway. The response to mating pheromone requires
the scaffold protein, STE5, while the response to osmotic shock
requires the scaffolds PBS2 and SHO1. The stimulus for inva-
sive growth under starvation conditions does not appear to
require a scaffold, but does use the conserved STE11/STE7/
FUS3 triad. It is notable that, with the completion of the
human genome project, homologs for STE5, PBS2, and SHO1
have not been identified in mammalian cells.
Based on binding to multiple components of a MAPK sig-
naling pathway, several mammalian proteins have been sug-
gested to function as MAPK scaffolds. For the Ras/MAPK
signaling pathway, three proteins—KSR, MP-1, and RKIP (46,
70)—have been implicated. In the stress pathways that use
JNK, JIP-1 and MEKK1 have been identified as potential
scaffolds (9, 10, 12, 69). In general, they are defined as scaffolds
based on their ability to bind to two or more components of the
kinase pathway. However, with the exception of JIP-1 (64), the
function of these proteins in vivo and whether or not they truly
scaffold MAPK components in vivo remains largely unre-
solved.
Theoretically, scaffolds may have a large number of nonmu-
tually exclusive functions (5, 30, 32). These properties include
linking specific extracellular signals with the MAPK pathway,
enhancing the kinetics of signaling (i.e., catalytic scaffolds), or
preventing cross talk between MAPK pathways (i.e., insula-
tors). STE5, PBS1, and SHO1 are good examples of scaffolds
that are required to link specific extracellular signals with the
MAPK signaling pathway. InaD, a scaffold important in Dro-
FIG. 6. KSR, MEK, and ERK exist in high-molecular-weight complexes in vivo . (A) Coimmunoprecipitation of KSR, ERK, and MEK. Brain
lysates were immunoprecipitated with anti-MEK antibodies and blotted for KSR and ERK (polyclonal antibodies). (B) Gel filtration analysis of
brain tissue from wild-type and KSR/ mice. Gel filtration fast-performance liquid chromatography fractions were subjected to SDS-PAGE,
transferred to nitrocellulose, and immunoblotted for KSR, MEK, ERK, and B-Raf. Apparent-molecular-weight standards are indicated above.
(C) Wild-type brain lysates were treated with anti-MEK antibody, followed by treatment with secondary anti-rabbit antibodies or control IgG
antibodies, followed by treatment with secondary anti-rabbit antibodies. Each sample was then used for gel filtration. Fast-performance liquid
chromatography fractions were immunoblotted for KSR, ERK, MEK, and B-Raf.
3042 NGUYEN ET AL. MOL. CELL. BIOL.
 o
n
 January 6, 2014 by W
ashington University in St. Louis
http://m
cb.asm
.org/
D
ow
nloaded from
 
sophila photoreceptor signal transduction, appears to function
as a catalytic scaffold because signaling in its absence still
occurs but with reduced efficiency and intensity (59).
Since ERK activation was not abolished and was attenuated
in the KSR/ mouse to the stimulation of multiple agonists,
KSR does not appear to function as a specificity determinant in
the MAPK pathway. Rather, KSR functions as a catalytic scaf-
fold that enhances the kinetic efficiency of MAPK signaling.
We suspect that KSR facilitates MAPK activation by preas-
sembling components and/or by helping to deliver cytoplasmic
MEK and ERK to Ras and Raf at the plasma membrane (37,
39). Since Raf did not appear to be bound to KSR, a specificity
scaffold, if one exists, might be predicted to couple Raf with
Ras. In fact, Sur-8, a potential adaptor/scaffold molecule iden-
tified in C. elegans, may function by preassembling Raf with
Ras (33, 50). It is also interesting that STE5, PBS1, and SHO1
all bind to STE11, the ortholog of Raf-1, whereas our studies
suggest that KSR does not bind to Raf-1 or B-Raf in vivo.
Thus, KSR does not appear to function like STE5. It will be
interesting to determine whether other proteins, such as MP-1
and RKIP, fulfill the criteria as scaffolds and whether they have
functions that are distinct from those of KSR.
Phenotype of KSR-deficient mice. Given the significant im-
pairment of ERK activation to multiple stimuli, we were sur-
prised that KSR-deficient mice develop normally. However,
precedence for the plasticity of developmental processes can
be found in several other mouse models wherein molecules
central to the Ras/MAPK pathway were ablated. For example,
development proceeds normally in mice deficient for N-Ras or
H-Ras (19), and mice deficient for ERK1 exhibit only a mod-
erate defect in T-cell development (44).
Alternatively, other mammalian KSR family members may
exist that can replace KSR function during development. In C.
elegans, another potential KSR family member protein, KSR2/
Pex-1, was recently cloned. RNA-mediated interference of
KSR2/Pex-1 in a KSR/ background demonstrates that the
loss of both isoforms is lethal in the worm (42). Lethality in the
complete absence of KSR is consistent with the finding that the
loss of the single KSR isoform in Drosophila is also lethal. It
seems very likely, therefore, that other KSR family members
will in turn be discovered in the mouse and human genomes. It
is important to note, however, that if another form of KSR
does exist in mouse, its expression is not sufficient to restore
ERK activation nor to prevent the loss of high-molecular-
weight signaling complexes in the brain tissue that we exam-
ined. It is possible that the residual level of ERK activity that
we detected may be due to another isoform of KSR, but it is
equally possible that other potential KSR family members will
turn out to function in a tissue-specific fashion.
Since the Ras/MAPK pathway is thought to be critical for
the positive selection of T cells (reviewed in references 28 and
49), it is also surprising that we were unable to detect any
significant defects in T-cell development. While it is possible
that the residual ERK activity in the KSR-deficient mice is
sufficient to mediate positive selection, recent data support the
idea that the Ras/MAPK pathway may not be as important for
T-cell-positive selection as previously believed. The original
studies were based on transgenic animals that express domi-
nant-negative forms of Ras, Raf, and MEK (1, 2, 43). How-
ever, studies with dominant-negative MAPK proteins trans-
duced by retroviruses (8) or with mice deficient for H-Ras or
N-Ras (19) do not support the results of the original transgenic
studies. We suspect that the Ras/MAPK signaling pathways
may be more involved in mediating processes such as cell
growth and proliferation and are less critical in instructive,
developmental decisions.
In conclusion, we have established that KSR fulfills the gen-
erally accepted criteria of a scaffold (5, 25, 37). It participates
in helping to generate high-molecular-weight multiprotein sig-
naling complexes that simultaneously contain at least three
components of the signaling pathway: KSR, MEK, and ERK.
While it has been previously suggested that Raf might be a
component of this signaling complex (56, 66), our results dem-
onstrate that the high-molecular-weight complexes containing
Raf are independent of the KSR/MEK/ERK complexes. It is
possible that signaling may induce an association between the
two complexes, but such experiments are technically not fea-
sible at the present time. Lastly, our data are consistent with
the role of KSR as a general positive mediator of Ras/MAPK
signaling; ERK stimulation in the absence of KSR was atten-
uated in a variety of systems, including tumor growth and
T-cell activation. Given that most components of the signaling
pathways have been identified, the challenges for signal trans-
duction in the next decade will be to determine how signaling
FIG. 7. Loss of KSR expression inhibits tumor formation in mam-
mary epithelial cells mediated by polyomavirus MT. Female litter-
mates were genotyped for transgenic expression of polyomavirus MT
(MT) and KSR status (either KSR/ or KSR/). These mice were
examined for the development of mammary tumors starting at the age
of 3 weeks. Tumors were detected by palpating all five pairs of mam-
mary glands on each mouse daily. The onset of tumor formation in
MT KSR/ mice (n 	 9) was 35  8 days. The onset of tumor
formation in MT KSR/ mice (n 	 8) was 65  9 days.
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pathways are regulated and modified in time and space. It is
clear that understanding the function of scaffolds will play the
central role in these processes.
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